+44 (0) 1223 755950
+1 832 327 7413
Nuclear Receptor Subfamily 2 Group C Member 2 (NR2C2) Antibody
REQUEST MORE INFO
Catalogue No: abx030944
Price:
US$326.25
(Size: 80 µl)
Reviews: 
(0 Publications and Reviews)
(0 Publications and Reviews)
Click on the image to see the image legend
Members of the nuclear hormone receptor family, such as NR2C2, act as ligand-activated transcription factors. The proteins have an N-terminal transactivation domain, a central DNA-binding domain with 2 zinc fingers, and a ligand-binding domain at the C terminus. The activated receptor/ligand complex is translocated to the nucleus where it binds to hormone response elements of target genes (Yoshikawa et al., 1996 [PubMed 8661150]).
Research Articles on Nuclear Receptor Subfamily 2 Group C Member 2 (NR2C2)
| Target | Nuclear Receptor Subfamily 2 Group C Member 2 (NR2C2) |
| Clonality | Polyclonal |
| Reactivity | Human |
| Tested Applications | ELISA, WB, IF/ICC |
| Host | Rabbit |
| Recommended dilutions | WB: 1/1000, IF/ICC: 1/10 - 1/50. Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Immunogen | KLH-conjugated synthetic peptide between 438-466 amino acids from the C-terminal region of human NR2C2. |
| Isotype | IgG |
| Form | Liquid |
| Purification | Purified through a protein A column, followed by peptide affinity purification. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| UniProt Primary AC | P49116 (UniProt, ExPASy) |
| UniProt Secondary AC | A8K3H5, B6ZGT8, P55092 |
| UniProt Entry Name | NR2C2_HUMAN |
| NCBI Accession | NP_003289.2 |
| KEGG | hsa:7182 |
| String | 9606.ENSP00000483059 |
| Molecular Weight | Calculated MW: 65.4 kDa |
| Buffer | PBS containing 0.09% sodium azide. |
| Specificity | Predicted to react with Mouse and Rat NR2C2. |
| Availability | Shipped within 5-10 working days. |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |